NIH Plans to Disband RAC

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 7
Volume 5
Issue 7

Bethesda , Md--NIH director Harold Varmus has announced plants to disband the Recombinant DNA Advisory Committee (RAC). The committee was formed in 1975 as a panel of 24 scientists, ethicists, and others at NIH dedicated to holding those in the field of biogenetics accountable to the public.

Bethesda , Md--NIH director Harold Varmus has announced plantsto disband the Recombinant DNA Advisory Committee (RAC). The committeewas formed in 1975 as a panel of 24 scientists, ethicists, andothers at NIH dedicated to holding those in the field of biogeneticsaccountable to the public.

The RAC created the first safety guidelines for genetically engineeringmicrobes, instituted a formal review system for studies involvinginsertion of new genes into humans, and, in 1990, gave the firstapproval of a human gene therapy experiment. RAC approval wasrequired before the FDA would consider any gene therapy proposal.

Now, Dr. Varmus believes the RAC is no longer necessary, as theFDA can handle all new proposals with the help of ad hoc committeesconvened as needed.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
2 experts in this video
2 experts in this video
Considering which non–muscle-invasive bladder cancer cases may be cured by surgery alone may help mitigate overtreatment in this patient group.
Related Content